Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
As CRISPR therapies move into clinical testing, David Schaffer and colleagues review a raft of different delivery technologies being road tested to address cargo capacity limitations, maximize potency, minimize off-target effects and avoid immunogenicity.
The Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) provides a comprehensive and forward-looking overview of industry’s experience with viral contamination of cell cultures used to produce recombinant proteins.